FOR IMMEDIATE RELEASE
2016 ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED
LUPUZOR™ SYMPOSIUM: 8 &
RESOLUTION |
FOR + DISCRETION |
% |
AGAINST |
% |
WITHHELD |
1 |
42,327,430 |
99.90 |
40,400 |
0.10 |
25,000 |
2 |
42,307,657 |
99.86 |
60,173 |
0.14 |
25,000 |
3 |
42,352,430 |
99.90 |
40,400 |
0.10 |
0 |
4 |
42,352,430 |
99.90 |
40,400 |
0.10 |
0 |
5 |
42,344,328 |
99.89 |
48,502 |
0.11 |
0 |
Special Resolution |
42,327,503 |
99.87 |
53,502 |
0.13 |
11,825 |
Lupuzor Symposium : Key Presenter : Prof. Sylviane Muller
As announced at the recent Preliminary Results, a Lupuzor™ Symposium is being hosted where Prof. Muller, inventor of Lupuzor™ will present on the unique 'Mechanism of Action' of Lupuzor™, also known by its chemical name 'Forigerimod' or 'P140'. Prof. Muller will also provide further evidence of the role the P140 molecule can take in the potential treatment of other autoimmune diseases.
Investor meetings as part of this Symposium are being held on both days. A sell-side analyst and media briefing will be held on 9 June @
For further information please see the Company's web site, www.immupharma.org, or contact:
-Ends-
For further information please contact:
|
|
Notes to Editors
ImmuPharma is a pharmaceutical development company listed since 2006 on AIM of the
ImmuPharma announced on
Lupuzor™
Lupuzor™ (also referred to as Forigerimod, or P140) is ImmuPharma's lead compound and a potential treatment for lupus (or Systemic Lupus Erythematosus), a chronic, potentially life-threatening auto-immune disease. Lupuzor™ has a novel mechanism of action aimed at modulating the body's immune system so that it does not attack healthy cells, and avoids causing adverse side effects. It has the potential to halt the progression of the disease in a substantial proportion of patients.
Lupuzor™ has been granted Fast Track status by the US FDA and approval to start Phase III under Special Protocol Assessment (SPA). This SPA was subsequently amended due to its strong safety and efficacy profile to allow for a reduced number of patients in the pivotal Phase III trial thereby reducing the projected cost and time of development considerably.
The pivotal Phase III clinical study is entitled "A 52-Week, Randomized, Double-Blind,
Commercial Opportunity
There are an estimated five million people globally suffering from Lupus, with approximately 1.5 million patients in the US, Europe and Japan (Source:
This information is provided by RNS